ASGCT’s Q1 2026 Landscape Report pointed to accelerating regulatory and funding activity across gene and RNA therapies, with an increase in startup funding and a reported uptick in approval pace. ASGCT CEO David Barrett highlighted that 42 gene therapies and 38 RNA therapies have been approved worldwide, alongside 76 non-genetically modified cell therapies. He also cited a 30% increase in startup funding versus Q1 2025 and noted that regulatory pace is “starting to pick up.” The report estimates more than 4,200 therapies in development and provided a pipeline breakdown across Phase I–III gene therapy trials, with a growing share of trials aimed at non-oncology indications.